Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Fallopian Tube Neoplasms 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioblastoma 2Uveal Melanoma 1Thymus Neoplasms 1Thymoma 1Stomach Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor 1Sarcoma 1Rectal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Leukemia, Myeloid, Acute 1Glioma 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Cytopenia 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

sintilimab 2pembrolizumab 2Nivolumab 2Immune Checkpoint Inhibitors 2Bevacizumab 2relatlimab 1epacadostat 1dabrafenib 1copanlisib 1atezolizumab 1Tiragolumab 1Oxaliplatin 1Cetuximab 1Capecitabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Spinocerebellar Degenerations × epacadostat × Clear all
NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

University of Pittsburgh

Phase 1/2 Withdrawn
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡